.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Recent Advances in the Treatment of Chronic GVHD: ASH 2024

Panelists discuss how recent advances in chronic GVHD treatment, including emerging therapies like ruxolitinib, ibrutinib, and belumosudil, are reshaping management strategies by emphasizing early intervention, treatment sequencing, and the potential of combination therapies to improve patient outcomes.

EP. 1: Understanding Graft-VS-Host Disease (GVHD) Basics

December 23rd 2024

Panelists discuss how graft-vs-host disease (GVHD) is a complex immune-mediated condition, highlighting the differences between acute and chronic GVHD, the associated risk factors, prognosis, and the impact of increased cyclophosphamide use on the clinical presentation of the disease.